Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$15.27 - $19.72 $2.58 Million - $3.33 Million
169,074 New
169,074 $2.62 Billion
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $1.1 Million - $2.97 Million
167,510 New
167,510 $2.97 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $32,387 - $52,495
8,241 Added 5.83%
149,674 $835,000
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $18,137 - $30,317
-5,366 Reduced 3.66%
141,433 $552,000
Q1 2022

May 11, 2022

BUY
$5.06 - $8.77 $4,720 - $8,182
933 Added 0.64%
146,799 $809,000
Q4 2021

Feb 11, 2022

BUY
$7.33 - $9.32 $39,530 - $50,262
5,393 Added 3.84%
145,866 $1.24 Million
Q3 2021

Nov 12, 2021

BUY
$7.01 - $11.37 $123,411 - $200,168
17,605 Added 14.33%
140,473 $1.22 Million
Q2 2021

Aug 11, 2021

SELL
$9.4 - $16.85 $245,170 - $439,481
-26,082 Reduced 17.51%
122,868 $1.3 Million
Q1 2021

May 13, 2021

SELL
$13.08 - $49.6 $237,545 - $900,785
-18,161 Reduced 10.87%
148,950 $2.39 Million
Q4 2020

Feb 09, 2021

BUY
$36.36 - $52.71 $460,499 - $667,572
12,665 Added 8.2%
167,111 $7.72 Million
Q3 2020

Nov 12, 2020

BUY
$22.61 - $38.9 $1.79 Million - $3.09 Million
79,342 Added 105.64%
154,446 $5.43 Million
Q2 2020

Aug 12, 2020

BUY
$13.87 - $28.44 $1.04 Million - $2.14 Million
75,104 New
75,104 $1.83 Million

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.